This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Ittipat Meewan: Innovator in HCV Protease Inhibitors
Introduction: Ittipat Meewan is a prominent inventor based in San Diego, California, known for his significant contributions to the field of antiviral drug development. His work primarily focuses on the design and synthesis of novel compounds aimed at combating Hepatitis C virus (HCV) infections.
Latest Patents: Ittipat holds a patent for HCV protease inhibitors, which target the HCV NS3/4A protease, a critical enzyme for viral replication. His innovative approach involves screening and synthesizing a new class of small molecules based on tryptophan derivative scaffolds. These inhibitors have shown efficacy against both wild-type and mutant forms of the protease.
Career Highlights: Ittipat's research has led to the identification of twenty-two compounds that inhibit HCV, with effective concentrations ranging from 0.64 to 63 μM. Notably, compound 22 emerged as the most active inhibitor in his series, demonstrating a comparable inhibition profile for common mutant strains of HCV. His work highlights the potential for developing effective treatments that remain potent against drug-resistant variants.
Collaborations: Throughout his career, Ittipat has collaborated with esteemed colleagues, including Ruben Abagyan, to enhance the understanding and development of antiviral therapies. Their combined expertise has contributed to the advancement of innovative